Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells

Cell Death and Disease - Tập 7 Số 3 - Trang e2135-e2135
Gaurav Pathria1, Bhavuk Garg1, Viola Borgdorff1, Kanika Garg1, Christine Wagner1, Giulio Superti‐Furga2, M. Goos1
1Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, Austria
2CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

Tóm tắt

AbstractMITF (microphthalmia-associated transcription factor) is a frequently amplified lineage-specific oncogene in human melanoma, whose role in intrinsic drug resistance has not been systematically investigated. Utilizing chemical inhibitors for major signaling pathways/cellular processes, we witness MITF as an elicitor of intrinsic drug resistance. To search kinase(s) targets able to bypass MITF-conferred drug resistance, we employed a multi-kinase inhibitor-directed chemical proteomics-based differential affinity screen in human melanocytes carrying ectopic MITF overexpression. A subsequent methodical interrogation informed mitotic Ser/Thr kinase Aurora Kinase A (AURKA) as a crucial regulator of melanoma cell proliferation and migration, independent of the underlying molecular alterations, including TP53 functional status and MITF levels. Crucially, assessing the efficacy of investigational AURKA inhibitor MLN8237, we pre-emptively witness the procurement of a molecular program consistent with acquired drug resistance. This involved induction of multiple MAPK (mitogen-activated protein kinase) signaling pathway components and their downstream proliferation effectors (Cyclin D1 and c-JUN) and apoptotic regulators (MITF and Bcl-2). A concomitant AURKA/BRAF and AURKA/MEK targeting overcame MAPK signaling activation-associated resistance signature in BRAF- and NRAS-mutated melanomas, respectively, and elicited heightened anti-proliferative activity and apoptotic cell death. These findings reveal a previously unreported MAPK signaling-mediated mechanism of immediate resistance to AURKA inhibitors. These findings could bear significant implications for the application and the success of anti-AURKA approaches that have already entered phase-II clinical trials for human melanoma.

Từ khóa


Tài liệu tham khảo

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–954.

Jang S, Atkins MB . Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther 2014; 95: 24–31.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809–819.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014; 508: 118–122.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683–695.

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968–972.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973–977.

Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085–3096.

Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013; 504: 138–142.

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251–255.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500–504.

Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell 2015; 27: 574–588.

Levy C, Khaled M, Fisher DE . MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006; 12: 406–414.

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436: 117–122.

Goding CR . Commentary. A picture of Mitf in melanoma immortality. Oncogene 2011; 30: 2304–2306.

Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A et al. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst 2013; 105: 33–46.

Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 2013; 23: 302–315.

Borgdorff V, Rix U, Winter GE, Gridling M, Muller AC, Breitwieser FP et al. A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene 2014; 33: 2531–2539.

Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR et al. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst 2012; 104: 1673–1679.

Wellbrock C, Marais R . Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 2005; 170: 703–708.

Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R . Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 2008; 3: e2734.

Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov 2014; 4: 816–827.

Zhang J, Yang PL, Gray NS . Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28–39.

Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127–132.

Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008; 6: 760–769.

Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010; 115: 5202–5213.

Pathria G, Wagner C, Wagner SN . Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J Invest Dermatol 2012; 132: 2780–2790.

Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T et al. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene 2012; 31: 1217–1227.

Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005; 433: 764–769.

Davis S, Vanhoutte P, Pages C, Caboche J, Laroche S . The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. J Neurosci 2000; 20: 4563–4572.

Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M et al. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 2007; 11: 447–460.

Bertolotto C, Abbe P, Hemesath TJ, Bille K, Fisher DE, Ortonne JP et al. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol 1998; 142: 827–835.

Mertz KD, Pathria G, Wagner C, Saarikangas J, Sboner A, Romanov J et al. MTSS1 is a metastasis driver in a subset of human melanomas. Nat Commun 2014; 5: 3465.

Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC et al. An integrated approach to uncover drivers of cancer. Cell 2010; 143: 1005–1017.

Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004; 36: 55–62.

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J et al. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 2015; 75: 181–193.

He W, Zhang MG, Wang XJ, Zhong S, Shao Y, Zhu Y et al. AURKA suppression induces DU145 apoptosis and sensitizes DU145 to docetaxel treatment. Am J Transl Res 2013; 5: 359–367.

Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W . Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008; 68: 8998–9004.

Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One 2010; 5: e10770.

Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP et al. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem 2012; 287: 29887–29898.

Jalili A, Moser A, Pashenkov M, Wagner C, Pathria G, Borgdorff V et al. Polo-like kinase 1 is a potential therapeutic target in human melanoma. J Invest Dermatol 2011; 131: 1886–1895.

Ice RJ, McLaughlin SL, Livengood RH, Culp MV, Eddy ER, Ivanov AV et al. NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors. Cancer Res 2013; 73: 3168–3180.

Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006; 125: 1269–1281.

Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Iida M et al. Molecular network associated with MITF in skin melanoma development and progression. J Skin Cancer 2011; 2011: 730170.

Caputo E, Miceli R, Motti ML, Tate R, Fratangelo F, Botti G et al. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. J Transl Med 2014; 12: 216.

Clark EA, Golub TR, Lander ES, Hynes RO . Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532–535.

Ke N, Albers A, Claassen G, Yu DH, Chatterton JE, Hu X et al. One-week 96-well soft agar growth assay for cancer target validation. Biotechniques 2004; 36: 826–828, 30, 32-3.

Thông tin
Thông tin xuất bản

Cell Death and Disease

Tập 7 Số 3

e2135-e2135

Thông tin tác giả